The treatment of inflammatory bowel disease (IBD)—ulcerative colitis (UC) and Crohn's
disease (CD)—has evolved beyond surgery with the introduction of biologic agents …

Introduction Dose escalation is one of the treatment approaches studied and suggested in
advanced therapies for Crohn's disease (CD) and ulcerative colitis (UC). This study aimed to …

Background Golimumab efficacy data in ulcerative colitis (UC) are limited to anti–tumor
necrosis factor α (TNF)-naive patients. The aim of this study was to assess the short-term …

Inflammatory response by different polarized macrophages has a critical role in a variety of
immunological pathophysiology, such as ulcerative colitis (UC). Herein, targeting the …

Abstract Background and Aims: Mucosal healing is associated with favourable therapeutic
outcomes in patients with ulcerative colitis [UC]. We investigated whether adalimumab …

Background Ulcerative colitis (UC) treatment is focused to achieve mucosal healing,
avoiding disease progression. The study aimed to evaluate the real-world effectiveness of …

Background Comparisons of second‐line anti‐tumour necrosis factor (TNF) agents and
vedolizumab are sparse. Aim To evaluate the effectiveness of anti‐TNF agents compared to …

Background Loss of response to infliximab or adalimumab in ulcerative colitis occurs
frequently, and dose escalation may aid in regaining clinical benefit. This study aimed to …

Background The impact of prior anti-TNF use on “real-life” outcomes of adalimumab therapy
in ulcerative colitis (UC) is not well known. Aim To compare the influence of prior anti-TNF …

Abstract Background and Aims Randomised trials have described the benefits of
adalimumab [ADA] for ulcerative colitis [UC]; however, few data are available on health …